#SFHS2614037AOPUVIZ Added to France’s Reimbursable Medicines List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds two presentations of OPUVIZ 40 mg/ml, an aflibercept injectable medicine, to France’s list of medicines reimbursed by social health insurance. The patient’s cost-sharing is removed for the covered uses listed in the annex. Reimbursement is limited to specific adult eye conditions, including wet age-related macular degeneration, visual impairment linked to several forms of macular edema, and myopic choroidal neovascularization. The treatment must be given by intravitreal injection by ophthalmologists experienced in this procedure.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds two OPUVIZ 40 mg/ml presentations to the reimbursable medicines list in France
- Removes patient cost-sharing for the specified covered eye-treatment indications
- Limits covered use to administration by experienced ophthalmologists through intravitreal injection
Obligations
What this law requires
Social health insurance reimbursement for OPUVIZ 40 mg/ml must be limited to the listed adult indications: wet retrofoveal age-related macular degeneration, visual impairment due to macular edema secondary to central retinal vein occlusion, specified diabetic macular edema after optimized diabetes management, macular edema secondary to branch retinal vein occlusion, and myopic choroidal neovascularization.
Patient cost-sharing must be removed for the reimbursable OPUVIZ 40 mg/ml presentations and indications listed in the annex under Article R. 160-8 of the Social Security Code.
OPUVIZ treatment must only be administered by intravitreal injection.
OPUVIZ intravitreal injections must only be administered by ophthalmologists experienced in this type of injection.